Select your country
Select a country to go to the website of the respective STADA sales company.
United Kingdom (4)
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent
- Ad hoc Release
- Investor News
Bad Vilbel, July 10, 2017 –
Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, announced today that it has submitted an application to the German Federal Financial Supervisory Authority (BaFin) for an exemption from the one-year exclusion period to submit a renewed voluntary public takeover offer under section 26(2) of the German Securities Acquisition and Takeover Act (WpÜG). STADA Arzneimittel AG has expressed its consent to the exemption from the exclusion period. The Management Board and the Supervisory Board hold the view that consenting to the exemption from the exclusion period is in the best interest of the company and its stakeholders. After having reviewed the parameters of an envisaged renewed voluntary public takeover offer as communicated by Nidda Healthcare Holding AG, the Management Board and the Supervisory Board agree that the renewed offer has been improved compared to the first one with regard to material aspects. This concerns in particular the offer price which will be increased by 0.25 Euro to 66.25 Euro, enhancing the offer’s transaction security, among other things, by lowering the minimum acceptance threshold from initially 75 percent to 63 percent and setting a shorter acceptance period of four weeks.
If the BaFin grants the exemption from the exclusion period upon the application by Nidda Healthcare AG, the acquiring company of Bain Capital and Cinven will then be in a position to make a renewed voluntary public takeover offer to STADA Arzneimittel AG shareholders, without having to adhere to the relevant exclusion period.
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org